{
  "trial_id": "NCT03238235",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Ambulant patients with BMD diagnosis confirmed by genetic testing.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Able and willing to give informed consent in writing.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Able to perform 6MWT at screening with a minimum distance of 200 m and maximum distance of 450 m.",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "exclusion": [
    {
      "criterion": "Exposure to another investigational drug within 3 months prior to the start of study treatment.",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "Use of any pharmacologic treatment, other than corticosteroids, that might have an effect on muscle strength or function within 3 months prior to the start of study treatment (e.g., growth hormone).",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "Patient has lower urinary tract symptoms including frequency, urgency, weak stream, incomplete emptying and intermittent flow for the past 9 months. He is otherwise healthy.",
  "_meta": {
    "topic_id": "24",
    "trial_id": "NCT03238235",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}